Regulatory · source year

2023 regulatory records

68 selected, source-linked regulatory records dated 2023. This is selective source coverage, not a complete timeline.

Dated records

68 selected records.

Peptide profiles

30 connected profiles.

Cited sources

68 distinct public records.

Cited chronology

Dated source records

All record types in 2023 →

December 2023

6 records

November 2023

15 records

Dasiglucagon

Federal Register notice 2023-26260

The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.

Source: Federal Register via GovInfo ↗

→

Pegcetacoplan

Federal Register notice 2023-26255

The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan.

Source: Federal Register via GovInfo ↗

→

Difelikefalin

Federal Register notice 2023-26106

The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.

Source: Federal Register via GovInfo ↗

→

Semaglutide

Federal Register notice 2023-25485

The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

Daptomycin

Federal Register notice 2023-24120

The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

October 2023

4 records

September 2023

6 records

Bivalirudin

Federal Register notice 2023-19013

The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

Source: Federal Register via GovInfo ↗

→

August 2023

7 records

Exenatide

Federal Register notice 2023-18241

The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

Exenatide

Federal Register notice 2023-18250

The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

Glucagon + 1 more

Federal Register notice 2023-18026

The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

Source: Federal Register via GovInfo ↗

→

Daptomycin

Federal Register notice 2023-16775

The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

June 2023

4 records

May 2023

5 records

Difelikefalin

Federal Register notice 2023-10710

The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.

Source: Federal Register via GovInfo ↗

→

April 2023

1 record

March 2023

9 records

Trofinetide

Federal Register notice 2023-06593

The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.

Source: Federal Register via GovInfo ↗

→

Icatibant

Federal Register notice 2023-04175

The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

Source: Federal Register via GovInfo ↗

→

February 2023

8 records

Calcitonin salmon

Federal Register notice 2023-03389

The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

Afamelanotide + 3 more

Federal Register notice 2023-03364

The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.

Source: Federal Register via GovInfo ↗

→

Desmopressin

Federal Register notice 2023-02442

The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

January 2023

3 records